🔎 Trials Near Me

Home › Linfoma di Burkitt › Arkansas

Studi clinici su Linfoma di Burkitt nello stato di Arkansas

5 studi su Linfoma di Burkitt cercano partecipanti presso sedi nello stato di Arkansas.

Città nello stato di Arkansas

Testo ufficiale dello studio (inglese)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 2
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 2
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 2
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Arkansas Children's Hospital, Little Rock
In reclutamentoFase 3
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

  • Arkansas Children's, Little Rock
  • Arkansas Children's Northwest, Springdale
In reclutamentoStudio osservazionale
Età da 1 a 23 · Tutti i sessi · Aggiornato il 25 feb 2026 · NCT07422337

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.